Onconetix (ONCO) Total Equity: History & Chart

Onconetix, Inc.(ONCO)

Biotechnology · Cincinnati, OH

$0.67-0.00 (-0.36%)

Delayed quote: Oct 6, 2026, 3:25 PM EDT

About Onconetix, Inc.

Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH). In its development pipeline, Onconetix is advancing a Streptococcus pneumoniae vaccine candidate, designed to prevent infectious middle ear infections in children and pneumonia in the elderly. Additionally, they are working on a universal influenza vaccine intended to provide comprehensive protection against all aggressive strains of the flu virus. Furthermore, Onconetix holds a license for an advanced norovirus S&P nanoparticle virus-like particle (VLP) vaccine platform from Cincinnati Children's. This adaptable platform is being leveraged to create vaccines for various infectious diseases, such as Marburg and monkeypox, among others. Established in 2018, the company was previously known as Blue Water Biotech, Inc., before changing its name to Onconetix, Inc. in December 2023. Its corporate headquarters are located in Cincinnati, Ohio.

Cincinnati, OH

2 employees

www.onconetix.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: David Allan White

View full financials

Total Equity

Basis: latest reported fiscal quarter. Source: stored company filings; unavailable inputs remain N/A.

The latest quarterly total equity is $13.47M with QoQ Growth of +14.66%. Total equity, also called shareholders' equity, is assets minus liabilities. The book value in P/B is the part attributable to common shareholders: total equity minus preferred stock.

Total Equity

ONCO Total Equity

$13.47M

Reported quarterly total equity; no daily interpolation. Q2 FY2026 (2026-06-30): $13.47M.

+412.94% over 10Y

ONCO P/B Ratio

Full P/B Ratio page

P/B Ratio

ONCO P/B Ratio Chart

0.18

FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock) Quote observation: 2026-10-06T19:27:27.567Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.

Quarterly Total Equity History

Period	Total Equity	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	$13.47M	+14.66%	+127.90%
Q1 FY2026Period end 2026-03-31	$11.75M	(25.49%)	+160.04%
Q4 FY2025Period end 2025-12-31	$15.76M	+367.22%	+64.03%
Q3 FY2025Period end 2025-09-30	$3.37M	(42.91%)	(90.05%)
Q2 FY2025Period end 2025-06-30	$5.91M	+30.83%	(79.21%)
Q1 FY2025Period end 2025-03-31	$4.52M	(53.00%)	N/A
Q4 FY2024Period end 2024-12-31	$9.61M	(71.66%)	N/A
Q3 FY2024Period end 2024-09-30	$33.91M	+19.30%	+231.29%
Q2 FY2024Period end 2024-06-30	$28.43M	N/A	+117.39%
Q1 FY2024Period end 2024-03-31	($21.53M)	(284.38%)	N/A
Q4 FY2023Period end 2023-12-31	($5.60M)	N/A	N/A
Q3 FY2023Period end 2023-09-30	$10.24M	(21.72%)	(60.22%)
Q2 FY2023Period end 2023-06-30	$13.08M	(33.60%)	(36.45%)
Q1 FY2023Period end 2023-03-31	$19.69M	(12.04%)	+19.11%
Q4 FY2022Period end 2022-12-31	$22.39M	(12.99%)	+1447.65%
Q3 FY2022Period end 2022-09-30	$25.73M	+25.06%	+879.91%
Q2 FY2022Period end 2022-06-30	$20.57M	+24.44%	N/A
Q1 FY2022Period end 2022-03-31	$16.53M	+1042.98%	N/A
Q4 FY2021Period end 2021-12-31	$1.45M	(44.91%)	N/A
Q3 FY2021Period end 2021-09-30	$2.63M	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.